PT-141 vs Melanotan 2 — Key Differences Explained for UAE Researchers
PT-141 vs Melanotan 2: Key Differences Explained for UAE Researchers
Reviewed by the CoreSup Research Team · Based on FDA pharmacology data, peer-reviewed receptor binding studies, and clinical trial publications · Updated March 2026
Both PT-141 and Melanotan 2 belong to the same peptide family, both emerged from the same research programme, and both produce sexual arousal effects through melanocortin receptors. But they are not interchangeable. One completed Phase 3 FDA trials and received regulatory approval. The other has never been studied beyond early clinical phases. One has a defined receptor profile. The other activates a broader spectrum with more unpredictable results. Understanding these differences is not academic — it affects safety, predictability, and what you can realistically expect.
This guide is a systematic comparison of PT-141 (bremelanotide) and Melanotan 2 covering structure, mechanism, receptor profiles, clinical evidence, and practical application. Every claim is referenced to published pharmacological data or official regulatory documents.
TL;DR: PT-141 is a refined derivative of Melanotan 2, engineered specifically for sexual function with reduced tanning and a tighter receptor profile (MC3R + MC4R). Melanotan 2 activates all 5 melanocortin receptors including MC1R (tanning), MC4R (appetite/sexual function), and MC5R (exocrine glands). PT-141 received FDA approval in 2019; Melanotan 2 has never completed a Phase 3 trial. For sexual function research with a defined safety record, PT-141 is the more appropriate compound.
Exploring research-grade melanocortin peptides? View the CoreSup peptides collection — lab-tested with full certificates of analysis, shipped across the UAE.
Common Origins: The University of Arizona Programme
To understand the differences between PT-141 and Melanotan 2, you need to start with alpha-melanocyte stimulating hormone (alpha-MSH) — the naturally occurring brain peptide that both compounds are derived from. Alpha-MSH is a 13-amino-acid hormone produced in the pituitary gland. It plays roles in skin pigmentation, appetite regulation, inflammation, and sexual function through its interactions with the five melanocortin receptor subtypes (MC1R through MC5R).
In the late 1980s and early 1990s, researchers at the University of Arizona began synthesising analogues of alpha-MSH with the goal of creating a "tanning pill" — a compound that could stimulate melanin production without UV exposure, potentially reducing skin cancer rates. The most successful candidate was Melanotan I (afamelanotide), followed by the more potent Melanotan 2.
That unexpected sexual arousal effect prompted researchers to ask: could you keep the sexual function properties while removing the tanning? The answer was PT-141 — a further-refined analogue that selectively downregulated MC1R activity (tanning) while preserving MC3R and MC4R activation (the receptors relevant to sexual desire and erectile function). Palatin Technologies acquired the compound and took it through clinical development over two decades, culminating in FDA approval as Vyleesi in 2019.
Structural Comparison
Both compounds are synthetic cyclic heptapeptides — 7-amino-acid cyclic analogues of alpha-MSH's core pharmacophore. The key structural difference lies in specific amino acid substitutions that shift receptor binding affinity:
| Property | PT-141 (Bremelanotide) | Melanotan 2 |
|---|---|---|
| Chemical name | Cyclo-(Nle4,D-Phe7)-α-MSH(4-10) | Ac-Nle4-c[Asp5,D-Phe7,Lys10]-α-MSH(4-10)-NH2 |
| Molecular weight | 1,025.2 Da | 1,024.2 Da |
| Structure | Cyclic lactam | Cyclic disulfide |
| Half-life | ~2.7 hours (FDA label) | ~1–3 hours (estimated, no approved label) |
| Primary receptors | MC3R, MC4R | MC1R, MC3R, MC4R, MC5R |
| Tanning effect | Minimal to none | Significant (MC1R activation) |
| FDA approval | Yes — Vyleesi (2019), HSDD in women | No approved indication |
| Phase 3 trial data | Yes — RECONNECT (1,247 participants) | No Phase 3 data for sexual function |
| Route of administration | Subcutaneous injection | Subcutaneous injection |
| Standard research dose | 1.75 mg (FDA-approved dose) | 0.5–1.0 mg (no approved dose) |
Receptor Profiles: Why the Difference Matters
The melanocortin receptor family has five subtypes, each with distinct tissue distribution and physiological roles. Understanding which receptors each compound activates explains the practical differences in their effects and side effect profiles.
MC1R — Pigmentation
MC1R is found primarily on melanocytes (skin cells responsible for pigmentation). Activation triggers melanin synthesis, producing the tanning effect. PT-141 has significantly reduced MC1R binding affinity compared to Melanotan 2. This is deliberate — the researchers at Palatin Technologies identified MC1R activity as unnecessary for sexual function and specifically engineered PT-141 to minimise it. Melanotan 2, by contrast, is a potent MC1R agonist — which is exactly why it was originally developed as a tanning compound.
MC3R — Central Metabolic and Sexual Function
MC3R is expressed in the hypothalamus and limbic system. Its role in sexual function is less well-defined than MC4R, but it participates in the central nervous system modulation of arousal and motivation. Both PT-141 and Melanotan 2 activate MC3R. PT-141's MC3R binding is considered part of its central pro-sexual mechanism alongside MC4R.
MC4R — The Key Sexual Function Receptor
MC4R is the primary receptor responsible for the sexual arousal effects of both compounds. It is expressed densely in hypothalamic regions including the paraventricular nucleus (PVN), which regulates sexual behaviour, appetite, and autonomic nervous system function. MC4R activation in the PVN has been directly linked to penile erection and sexual desire in both animal models and human clinical trials. Both PT-141 and Melanotan 2 are MC4R agonists — this is the mechanism through which they produce sexual effects.
MC5R — Exocrine Glands
MC5R is expressed in exocrine glands (sweat glands, sebaceous glands) and plays roles in sebum secretion and sweat production. Melanotan 2 activates MC5R, which may contribute to some of its less-discussed side effects including altered sweating patterns. PT-141 has minimal MC5R activity, contributing to its cleaner side effect profile.
Clinical Evidence: A Stark Contrast
This is where the two compounds diverge most significantly. PT-141 has one of the most rigorous evidence bases of any sexual health peptide. Melanotan 2 has essentially none.
PT-141 Clinical Evidence
PT-141 progressed through the full FDA drug development pathway: Phase 1 safety trials, Phase 2 dose-finding studies, and Phase 3 efficacy trials. The pivotal programme was RECONNECT — two identical Phase 3 randomised, double-blind, placebo-controlled trials enrolling 1,247 premenopausal women with HSDD. The primary endpoints were patient-reported improvements in sexual desire scores and reductions in distress related to low desire. Both were met with statistical significance (P<0.001 vs placebo). Secondary endpoints included changes in the number of satisfying sexual events. Based on this data, the FDA approved bremelanotide 1.75 mg subcutaneous injection (Vyleesi) in June 2019.
For men specifically, a 2007 study presented at the American Urological Association found PT-141 (0.5 mg, 1.0 mg, and 2.0 mg intranasal) produced positive erectile responses in men with erectile dysfunction, including 33.5% of men who had previously failed to respond to sildenafil (Viagra). This demonstrates PT-141's potential as a second-line option for ED where PDE5 inhibitors have failed.
Melanotan 2 Clinical Evidence
Melanotan 2's clinical evidence for sexual function amounts to a handful of small Phase 1/2 studies and a large body of anecdotal reports. The compound has never been taken through a randomised controlled Phase 3 trial for any sexual health indication. It has no FDA approval, no EMA approval, and no regulatory approval anywhere in the world. Most of what is "known" about its sexual effects comes from user forums, which are not a reliable evidence source. The data gap is not a minor footnote — it is a fundamental limitation that affects how confidently any effect or safety claim can be made.
Side Effect Comparison
| Side Effect | PT-141 (RECONNECT data) | Melanotan 2 (anecdotal / limited studies) |
|---|---|---|
| Nausea | 40.0% (vs 1.3% placebo) | Commonly reported; frequency unquantified |
| Flushing | 20.3% | Commonly reported |
| Headache | 11.3% | Reported |
| Blood pressure changes | Transient decrease (~6 mmHg systolic); transient increase possible | Reported; unpredictable; no Phase 3 data |
| Tanning / skin darkening | Minimal to none | Significant; can be permanent with repeated use |
| Spontaneous erections | Possible; dose-dependent | Commonly reported; harder to dose-control |
| Appetite suppression | Not reported at standard doses | Reported; MC4R-mediated |
| Moles / nevi changes | Not associated | Case reports of new moles and darkening of existing moles |
| Long-term safety data | Available (Phase 3 programme) | Not available from controlled studies |
The Melanotan 2 side effect profile that draws the most concern in dermatology is the potential for changes to existing moles (nevi). Several case reports have documented new mole formation and darkening of existing moles following Melanotan 2 use — a consequence of its potent MC1R activation. This is not a theoretical risk; it has been documented in peer-reviewed dermatology literature. PT-141, with its minimal MC1R activity, does not carry this concern at standard doses.
Practical Guidance for UAE Researchers
When PT-141 Is the Appropriate Choice
PT-141 is appropriate when the research focus is on sexual desire and arousal with a defined evidence base. Its FDA approval provides a pharmacological reference point — the 1.75 mg subcutaneous dose is the studied dose with a known side effect frequency. Anyone researching the central nervous system mechanisms of sexual desire, or investigating compounds in men who have not responded to PDE5 inhibitors, is working from a more reliable foundation with PT-141.
Why Melanotan 2's Broader Profile Is a Liability
Melanotan 2's activation of MC1R, MC3R, MC4R, and MC5R simultaneously means you cannot easily attribute any observed effect to a single receptor mechanism. For systematic research, this is a problem. The compound is pharmacologically messy. Its tanning effects are also relevant in a UAE context — uncontrolled skin pigmentation changes in a population with a wide range of skin tones is an outcome that most researchers would not want as an unintended variable.
Research-Grade PT-141 in the UAE
CoreSup supplies laboratory-verified PT-141 (bremelanotide) with full third-party certificates of analysis — tested for purity, identity, and potency. Delivered across Dubai, Abu Dhabi, and the UAE.
View PT-141 at CoreSupFrequently Asked Questions
What is the main difference between PT-141 and Melanotan 2?
PT-141 was engineered from Melanotan 2 to retain sexual function effects while minimising tanning. It has reduced MC1R activity and tighter selectivity for MC3R and MC4R — the receptors governing sexual desire in the brain. Melanotan 2 activates all five melanocortin receptors, giving it a broader and less predictable effect and side effect profile.
Is Melanotan 2 or PT-141 safer?
PT-141 has a significantly more established safety record. It completed Phase 3 FDA-regulated trials with 1,247 participants and received regulatory approval. Melanotan 2 has never completed a Phase 3 trial for any indication. Its broader receptor activation and documented dermatological risks (mole changes) add additional uncertainty not present with PT-141.
Does PT-141 cause tanning like Melanotan 2?
PT-141 produces significantly less tanning than Melanotan 2 because its MC1R activity was substantially reduced during development. Some users report mild transient flushing, but the dramatic tanning effect of Melanotan 2 is not characteristic of PT-141 at standard doses.
Can you use PT-141 and Melanotan 2 together?
Combining them is not recommended. Both activate overlapping melanocortin receptors, and concurrent use would amplify side effects — particularly nausea, blood pressure changes, and flushing — without proportionally increasing sexual function benefits. There is no published clinical data supporting combination use.
Which peptide is better for erectile dysfunction — PT-141 or Melanotan 2?
PT-141 is better studied for erectile dysfunction. A 2007 AUA study found it produced positive results in 33.5% of men who had previously failed sildenafil. Melanotan 2 has anecdotal reports of similar effects but lacks comparable controlled trial data. For evidence-based ED research, PT-141 is the more appropriate compound.
CoreSup stocks pharmaceutical-grade bacteriostatic water (10ml, 0.9% benzyl alcohol) with same-day delivery across Dubai and all UAE emirates.
Shop Bacteriostatic Water →For a complete overview of PT-141, read the CoreSup PT-141 Complete Guide. For dosage protocols, see our PT-141 Dosage Guide.
Shop Featured Products
Related Products
Written by Amir Arsalan
Core Sup Research Team · Peptide & Supplement Specialists, Dubai UAE
Core Sup's editorial team is composed of specialists in peptide therapy, SARMs, and sports supplementation with direct experience in the UAE market. All content is written to current research standards and reviewed before publication.
Last reviewed: March 2026 · About Core Sup
